blog Early Trial Finds Personalised Vaccine Approach Workable in Ovarian CancerBy Abigail WardOctober 16, 2026 Researchers say a bespoke neoantigen vaccine given with nivolumab proved feasible and acceptably safe in an early trial in platinum-sensitive ovarian cancer.